Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

Build and they will come. Billionaires Sabin Aboitiz and Ramon Ang are keen on making the Philippines more accessible to tourists who are big spenders when vacationing here, a country known for ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks. In his second appearance on Squawk on the Street after the ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...

Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis (CF) treatments, but both therapies come with boxed warnings for potential ...

It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid analgesic. Vertex Pharmaceuticals said Friday the FDA has approved its next cystic fibrosis product ...

Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue ...